-
Lonza Opens Facility for ADC Payload Manufacturing
contractpharma
November 06, 2020
Lonza, a specialty CDMO partner to the biopharma industry, has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp, Switzerland site.
-
Samsung Biologics Expands in China
contractpharma
November 05, 2020
Samsung Biologics has entered into a partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC)...
-
CStone and LegoChem to jointly develop novel antibody drug conjugate
pharmaceutical-technology
October 30, 2020
CStone Pharmaceuticals and LegoChem Biosciences (LCB) have signed a licensing agreement for the development and commercialisation of a potential antibody-drug conjugate (ADC), LCB71.
-
Iksuda Therapeutics exercises licensing rights from University of Goettingen
pharmatimes
October 16, 2020
UK-based biotech company Iksuda Therapeutics has executed its option to secure exclusive worldwide rights to develop a new class of tumour-activated prodrug payloads from the University of Goettingen.
-
Exelixis, NBE join forces for discovery and development of ADCs for cancer
pharmaceutical-business-review
September 24, 2020
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific ...
-
$65 million expansion to HPAPI manufacturing facility
europeanpharmaceuticalreview
September 24, 2020
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
-
MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities
contractpharma
September 18, 2020
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.
-
Exelixis and Catalent Enter ADC Partnership
contractpharma
September 17, 2020
Collaboration, license and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag bioconjugation technology.
-
Abzena Receives $10M Investment from Biospring Partners
contractpharma
July 29, 2020
New capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20.
-
Trio Pharmaceuticals, Ajinomoto Bio-Pharma Announce Antibody Therapeutic Collaboration
americanpharmaceuticalreview
May 04, 2020
Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services announced a development collaboration agreement to evaluate AJICAP™.